ArticleIranian journal of pharmaceutical research : IJPR
Genistein Exerts Anti-proliferative Effects by Regulating Apoptosis and Autophagy-Related Genes and MicroRNAs in Human Urinary Bladder Neoplasm EJ138 Cells: An Experimental and Bioinformatic Study.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Looking at the fraction with Annexin V⁺ and propidium iodide⁺: insights into cell death types from preclinical studies in solid and haematological cancers.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BC) is the most prevalent urogenital malignancy. Recently, the combination of natural compounds with chemotherapeutic agents has gained attention. Genistein, a natural flavonoid, exhibits anti-cancer properties and represents a promising candidate for treating various cancerous cells due to its cytotoxic potential and minimal adverse effects. Objectives: This study aimed to evaluate the anti-cancer effects of genistein by regulating potential target genes and microRNAs involved in apoptosis and autophagy in EJ138 BC cells. Methods: EJ138 BC cells were treated with different concentrations of genistein, and cell viability was assessed using the MTT assay. To determine the apoptotic rate of EJ138 BC cells following genistein treatment, flow cytometry with Annexin V/PI staining was performed. Additionally, real-time PCR was conducted to analyze the expression of miR-27a, miR-151, apoptotic genes (caspase-3, caspase-9), and autophagic genes (ATG12, Beclin1) after 48 hours of genistein treatment. Statistical analysis was carried out using SPSS V.22, with independent t-tests and one-way ANOVA. Results were considered statistically significant at P < 0.05. Results: Our findings demonstrated that genistein inhibited the proliferation, growth, and viability of EJ138 BC cells and induced cell death. Real-time PCR results confirmed that genistein significantly upregulated miR-27a (P < 0.01), ATG12 (P < 0.01), Beclin1 (P < 0.05), caspase-3 (P < 0.001), and caspase-9 (P < 0.0001), while downregulating miR-151 expression (P < 0.05). Conclusions: The results of this study suggest that genistein suppresses the proliferation and growth of human BC cells by modulating genes and microRNAs involved in apoptosis and autophagy. Therefore, genistein may serve as a novel therapeutic agent for BC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.